|
|
|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Cabaletta Bio, Inc. (CABA) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
91,470,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Co.'s proprietary technology utilizes Chimeric AutoAntibody Receptor, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Co.'s main CAAR T cell product candidate was designed based on the Chimeric Antigen Receptor, T cell technology that is marketed for the treatment of B cell cancers. Co.'s initial focus is mucosal pemphigus vulgaris, which is an autoimmune blistering disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-10-23 |
2025-07-22 |
2025-01-21 |
2024-01-22 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
Gavel Steve |
Chief Commercial Officer |
|
2026-01-21 |
4 |
B |
$2.27 |
$50,215 |
D/D |
22,170 |
22,170 |
0.01 |
- |
|
Tomasello Shawn |
|
|
2026-01-21 |
4 |
B |
$2.21 |
$50,322 |
I/I |
22,725 |
22,725 |
0.01 |
- |
|
Simon Mark |
|
|
2026-01-21 |
4 |
B |
$2.28 |
$25,261 |
D/D |
11,061 |
147,205 |
0.01 |
- |
|
Chang David J. |
Chief Medical Officer |
|
2026-01-21 |
4 |
B |
$2.26 |
$19,888 |
D/D |
8,800 |
8,800 |
0.01 |
- |
|
Binder Gwendolyn |
President, Science & Tech. |
|
2026-01-21 |
4 |
B |
$2.19 |
$24,763 |
D/D |
11,312 |
31,312 |
0.01 |
- |
|
Bollard Catherine |
|
|
2026-01-21 |
4 |
B |
$2.27 |
$9,982 |
D/D |
4,405 |
5,405 |
0.01 |
- |
|
Gerard Michael |
General Counsel |
|
2026-01-21 |
4 |
B |
$2.27 |
$14,979 |
D/D |
6,600 |
6,600 |
0.01 |
- |
|
Nichtberger Steven |
President & CEO |
|
2026-01-21 |
4 |
B |
$2.24 |
$100,778 |
D/D |
45,000 |
1,031,483 |
0.01 |
- |
|
Binder Gwendolyn |
See Remarks |
|
2024-01-19 |
4 |
AS |
$19.54 |
$215,439 |
D/D |
(11,000) |
20,000 |
|
- |
|
Binder Gwendolyn |
See Remarks |
|
2024-01-19 |
4 |
OE |
$1.01 |
$11,110 |
D/D |
11,000 |
31,000 |
|
- |
|
Binder Gwendolyn |
See Remarks |
|
2023-12-19 |
4 |
AS |
$21.76 |
$240,789 |
D/D |
(11,000) |
20,000 |
|
- |
|
Binder Gwendolyn |
See Remarks |
|
2023-12-19 |
4 |
OE |
$1.01 |
$11,110 |
D/D |
11,000 |
31,000 |
|
- |
|
Binder Gwendolyn |
See Remarks |
|
2023-11-20 |
4 |
AS |
$17.39 |
$196,014 |
D/D |
(11,000) |
20,000 |
|
- |
|
Binder Gwendolyn |
See Remarks |
|
2023-11-20 |
4 |
OE |
$1.01 |
$11,110 |
D/D |
11,000 |
31,000 |
|
- |
|
Binder Gwendolyn |
See Remarks |
|
2023-10-19 |
4 |
AS |
$13.32 |
$146,921 |
D/D |
(11,000) |
20,000 |
|
- |
|
Binder Gwendolyn |
See Remarks |
|
2023-10-19 |
4 |
OE |
$1.01 |
$11,110 |
D/D |
11,000 |
31,000 |
|
- |
|
Binder Gwendolyn |
See Remarks |
|
2023-09-19 |
4 |
AS |
$17.50 |
$193,220 |
D/D |
(11,000) |
20,000 |
|
- |
|
Binder Gwendolyn |
See Remarks |
|
2023-09-19 |
4 |
OE |
$1.01 |
$11,110 |
D/D |
11,000 |
31,000 |
|
- |
|
Binder Gwendolyn |
See Remarks |
|
2023-08-21 |
4 |
AS |
$13.41 |
$147,583 |
D/D |
(11,000) |
20,000 |
|
- |
|
Binder Gwendolyn |
See Remarks |
|
2023-08-21 |
4 |
OE |
$1.01 |
$11,110 |
D/D |
11,000 |
31,000 |
|
- |
|
Binder Gwendolyn |
See Remarks |
|
2023-07-19 |
4 |
AS |
$13.67 |
$152,022 |
D/D |
(11,000) |
20,000 |
|
- |
|
Binder Gwendolyn |
See Remarks |
|
2023-07-19 |
4 |
OE |
$1.01 |
$11,110 |
D/D |
11,000 |
31,000 |
|
- |
|
Binder Gwendolyn |
See Remarks |
|
2023-06-20 |
4 |
AS |
$12.99 |
$142,925 |
D/D |
(11,000) |
20,000 |
|
- |
|
Binder Gwendolyn |
See Remarks |
|
2023-06-20 |
4 |
OE |
$1.01 |
$11,110 |
D/D |
11,000 |
31,000 |
|
- |
|
Binder Gwendolyn |
See Remarks |
|
2023-05-19 |
4 |
AS |
$11.81 |
$259,833 |
D/D |
(22,000) |
20,000 |
|
- |
|
48 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|